Lynn Rutkowski is a distinguished neuroscientist and pharmacologist with extensive expertise in translational medicine. She was formerly assistant vice president of translational medicine at Wyeth in Collegeville, PA and co-led the translational Medicine research collaboration in Scotland. She was head of product development at Neuronyx in Malvern, PA, where she worked on mesenchymal stem cell products with the late Hubert Schoemaker, co-founder of Cenotcor, one of the first biotech companies to produce therapeutic monoclonal antibodies. Before joining industry, Dr. Rutkowski had more than 15 years of academic research experience as a NIH-funded principal investigator with faculty appointments in neurology at University of Pennsylvania, University of Michigan and Johns Hopkins University, where she worked on Schwann cell biology and neurofibromatosis. Dr. Rutkowski received her PhD in pharmacology and toxicology with a focus on neuropharmacology from the University of Maryland, Baltimore.